This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

PharmaPoint: Rheumatoid Arthritis - United Kingdom Drug Forecast And Market Analysis Event-Driven Update

NEW YORK, Jan. 8, 2013 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

PharmaPoint: Rheumatoid Arthritis - United Kingdom Drug Forecast and Market Analysis Event-Driven Update

PharmaPoint: Rheumatoid Arthritis - United Kingdom Drug Forecast and Market Analysis Event-Driven Update


GlobalData has released its new Country report, "PharmaPoint: Rheumatoid Arthritis - United Kingdom Drug Forecast and Market Analysis Event-Driven Update". The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer's Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly's anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ's SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market.

UK physicians surveyed for this report typically follow guidelines such as NICE or BSR (British Society for Rheumatology), but also follow their own clinical experience as no two patients are the same. In the UK, about 65% of patient referrals at any stage come from PCPs. As in the US, most people seeking treatment are 55 years and older; however within this age group, males outnumber females by a small margin compared with the younger age groups.


- Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.- Detailed information on the key drugs in the United Kingdom including product description, safety and efficacy profiles as well as a SWOT analysis.- Sales forecast for the top drugs in United Kingdom from 2011 to 2022.- Analysis of the impact of key events as well the drivers and restraints affecting the United Kingdom rheumatoid arthritis market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return- Stay ahead of the competition by understanding the changing competitive landscape for rheumatoid arthritis- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential- Make more informed business decisions from insightful and in-depth analysis of rheumatoid arthritis drug performance in the United Kingdom- Obtain sales forecast from 2011-2022 in the United Kingdom1 Table of Contents1 Table of Contents 41.1 List of Tables 71.2 List of Figures 92 Introduction 102.1 Catalyst 102.2 Related Reports 113 Disease Overview 133.1 Etiology and Pathophysiology 133.1.1 Etiology 133.1.2 Pathophysiology 133.1.3 Prognosis 163.1.4 Quality of Life 163.2 Symptoms 174 Disease Management 184.1 Treatment Overview 214.2 UK 244.2.1 Diagnosis 244.2.2 Clinical Practice 245 Competitive Assessment 265.1 Overview 265.2 Strategic Competitor Assessment 265.3 Product Profiles - Major Brands 275.3.1 Enbrel (etanercept) 275.3.2 Humira (adalimumab) 335.3.3 Remicade (infliximab) 365.3.4 Simponi (golimumab) 405.3.5 Cimzia (certolizumab pegol) 445.3.6 Orencia (abatacept) 475.3.7 Actemra/RoActemra (tocilizumab) 515.3.8 Rituxan/MabThera (rituximab) 555.3.9 Methotrexate Sodium (numerous generic names) 595.3.10 DMARDs 626 Opportunity and Unmet Need 636.1 Overview 636.2 Unmet Needs 646.2.1 More rheumatologists in the field and physician knowledge of the disease 646.2.2 More cost-effective therapies through oral formulation and biosimilars 646.2.3 The development of predictive tests and discovery of biomarkers 646.2.4 The discovery of curative therapies 646.2.5 Improved drug safety and efficacy profiles 656.3 Gap Analysis 656.4 Opportunities 666.4.1 Predictive Tools for Diagnosis and Treatment 666.4.2 Target Specificity 667 Pipeline Assessment 677.1 Overview 677.2 Promising Drugs in Clinical Development 687.2.1 Tofacitinib (CP-690550) 697.2.2 Tabalumab (LY2127399) 767.2.3 Fostamatinib (previously R788) 797.2.4 RAVAX 837.2.5 Secukinumab (AIN457) 877.2.6 Masitinib (AB101) 917.2.7 Baricitinib (formerly LY3009104/INCB28050) 967.2.8 Sarilumab (REGN88/ SAR153191) 1007.2.9 Sirukumab (CNTO 136) 1038 Market Outlook 1068.1 United Kingdom 1068.1.1 Forecast 1068.1.2 Key Events 1098.1.3 Drivers and Barriers 1099 Appendix 1129.1 Abbreviations 1129.2 Bibliography 1149.3 Methodology 1229.4 Forecasting Methodology 1229.4.1 Diagnosed Rheumatoid Arthritis Patients 1229.4.2 Percent Drug-treated Patients 1239.4.3 Drugs Included in Each Therapeutic Class 1239.4.4 Launch and Patent Expiry Dates 1249.4.5 General Pricing Assumptions 1249.4.6 Individual Drug Assumptions 1259.4.7 Generic Erosion 1319.4.8 Pricing of Pipeline agents 1319.5 Physicians and Specialists Included in this Study 1329.6 Primary Research - Prescriber Survey 1329.7 About the Authors 1339.7.1 Analysts 1339.7.2 Global Head of Healthcare 1349.8 About GlobalData 1359.9 Contact Us 1359.10 Disclaimer 135

List of Tables

1.1 List of Tables

Table 1: Symptoms of Rheumatoid Arthritis 17

1 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,088.36 +58.15 0.32%
S&P 500 2,091.38 +9.50 0.46%
NASDAQ 4,809.8050 +36.3330 0.76%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs